Thornburg Investment Management Inc. Purchases 23,406 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Thornburg Investment Management Inc. lifted its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 138.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 40,345 shares of the biotechnology company's stock after purchasing an additional 23,406 shares during the quarter. Thornburg Investment Management Inc.'s holdings in Sarepta Therapeutics were worth $3,890,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of SRPT. Principal Securities Inc. acquired a new stake in shares of Sarepta Therapeutics during the 4th quarter worth $26,000. Montag A & Associates Inc. bought a new stake in shares of Sarepta Therapeutics during the 3rd quarter worth $30,000. Cary Street Partners Investment Advisory LLC lifted its position in shares of Sarepta Therapeutics by 154.0% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company's stock worth $31,000 after buying an additional 154 shares during the last quarter. CWM LLC lifted its position in shares of Sarepta Therapeutics by 178.7% during the 4th quarter. CWM LLC now owns 577 shares of the biotechnology company's stock worth $56,000 after buying an additional 370 shares during the last quarter. Finally, Fifth Third Bancorp lifted its position in shares of Sarepta Therapeutics by 1,215.8% during the 4th quarter. Fifth Third Bancorp now owns 1,000 shares of the biotechnology company's stock worth $96,000 after buying an additional 924 shares during the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Trading Down 1.0 %

Shares of SRPT stock traded down $1.36 on Friday, hitting $131.38. The company had a trading volume of 848,974 shares, compared to its average volume of 1,025,304. The firm has a market cap of $12.42 billion, a P/E ratio of 1,206.73 and a beta of 0.95. The stock's 50-day moving average is $126.36 and its two-hundred day moving average is $112.14. The company has a debt-to-equity ratio of 1.18, a quick ratio of 3.44 and a current ratio of 4.05. Sarepta Therapeutics, Inc. has a twelve month low of $55.25 and a twelve month high of $152.21.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.84. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The company had revenue of $413.50 million during the quarter, compared to analysts' expectations of $375.52 million. During the same quarter in the prior year, the firm posted ($1.44) earnings per share. The business's quarterly revenue was up 63.1% on a year-over-year basis. On average, equities research analysts anticipate that Sarepta Therapeutics, Inc. will post 2.68 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Dallan Murray sold 3,635 shares of the firm's stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $140.00, for a total transaction of $508,900.00. Following the completion of the sale, the insider now owns 18,125 shares of the company's stock, valued at $2,537,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 761 shares of the firm's stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $122.93, for a total value of $93,549.73. Following the completion of the sale, the director now owns 7,516 shares of the company's stock, valued at $923,941.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Dallan Murray sold 3,635 shares of the firm's stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $140.00, for a total value of $508,900.00. Following the completion of the sale, the insider now directly owns 18,125 shares of the company's stock, valued at approximately $2,537,500. The disclosure for this sale can be found here. Insiders sold 25,731 shares of company stock valued at $3,248,319 over the last 90 days. Company insiders own 7.70% of the company's stock.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Oppenheimer upgraded Sarepta Therapeutics from a "market perform" rating to an "outperform" rating and set a $180.00 price objective for the company in a research report on Tuesday. TheStreet upgraded Sarepta Therapeutics from a "d" rating to a "c-" rating in a research report on Monday, March 4th. Wedbush restated an "outperform" rating and set a $224.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. Evercore ISI upped their price objective on Sarepta Therapeutics from $108.00 to $138.00 and gave the stock an "in-line" rating in a research report on Tuesday, February 20th. Finally, JPMorgan Chase & Co. dropped their target price on Sarepta Therapeutics from $177.00 to $175.00 and set an "overweight" rating for the company in a research report on Friday, May 3rd. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, Sarepta Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $163.94.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.